Literature DB >> 10733346

Malignant astrocytoma cell attachment and migration to various matrix proteins is differentially sensitive to phosphoinositide 3-OH kinase inhibitors.

J Ling1, Z Liu, D Wang, C L Gladson.   

Abstract

Phosphoinositide 3-OH kinase (PI3-K) has been shown to play an important role in the signaling pathway necessary for cytoskeletal reorganization in non-astrocytic cells. We investigated the role of PI3-K in U-251 MG human malignant astrocytoma cell adhesion and migration. Attachment of U-251 MG cells to vitronectin, fibronectin, laminin, and collagen was inhibited in a concentration-dependent manner by two specific inhibitors of PI3-K (Wortmannin and LY294002). Attachment to vitronectin, fibronectin, and laminin was more sensitive to inhibition of PI3-K (45% inhibition at 10 nM Wortmannin) than attachment to collagen (25% inhibition at 100 nM Wortmannin). Similarly, migration toward these substrates showed differential sensitivity to inhibition. Attachment of the cells to these matrix proteins resulted in an increase in PI3-K activity, as compared to that of cells in suspension, with attachment to vitronectin resulting in the greatest increase in PI3-K activity. p125 focal adhesion kinase (p125FAK) was found to co-immunoprecipitate with PI3-K from the NP40-soluble cell fraction of a 1% NP40 detergent lysate of cells in the early stages of adhesion to vitronectin and fibronectin, but not during adhesion to collagen. The expression of p125FAK protein and level of phosphorylation were similar on adherence to all three substrates. These data indicate that the sensitivity of U-251MG cell attachment and migration to PI3-K inhibitors is substrate-dependent, and that complex formation of PI3-K and p125FAK correlates with this sensitivity to PI3-K inhibitors. Our data suggest a role for PI3-K and p125FAK complex formation in PI3-K activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10733346

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  2 in total

1.  Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.

Authors:  Jonathon J Parker; Kalen R Dionne; Rada Massarwa; Marci Klaassen; Nicholas K Foreman; Lee Niswander; Peter Canoll; B K Kleinschmidt-Demasters; Allen Waziri
Journal:  Neuro Oncol       Date:  2013-06-07       Impact factor: 12.300

Review 2.  The pathobiology of glioma tumors.

Authors:  Candece L Gladson; Richard A Prayson; Wei Michael Liu
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.